Literature DB >> 21677508

A case of thyroiditis during natalizumab therapy for multiple sclerosis.

S Oddo, A Laroni, A Uccelli, M Giusti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21677508     DOI： 10.1007/BF03347466

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  12 in total

Review 1.  Emerging therapies in relapsing-remitting multiple sclerosis.

Authors:  James J Marriott; Paul W O'Connor
Journal:  Rev Recent Clin Trials       Date:  2010-09

2.  Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study.

Authors:  L Durelli; B Ferrero; A Oggero; E Verdun; A Ghezzi; E Montanari; M Zaffaroni
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 3.  Safety profile of Tysabri: international risk management plan.

Authors:  P Iaffaldano; M D'Onghia; Maria Trojano
Journal:  Neurol Sci       Date:  2009-10       Impact factor: 3.307

Review 4.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

Review 5.  Alemtuzumab and multiple sclerosis: therapeutic application.

Authors:  Alireza Minagar; J Steven Alexander; Mohammad Ali Sahraian; Robert Zivadinov
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

6.  A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.

Authors:  Deborah Mannavola; Paola Coco; Guia Vannucchi; Rossella Bertuelli; Marco Carletto; Paolo G Casali; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  J Clin Endocrinol Metab       Date:  2007-06-26       Impact factor: 5.958

7.  Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.

Authors:  I Tamaskar; R Bukowski; P Elson; A G Ioachimescu; L Wood; R Dreicer; T Mekhail; J Garcia; B I Rini
Journal:  Ann Oncol       Date:  2007-10-24       Impact factor: 32.976

8.  Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.

Authors:  Elaine Wong; Lee S Rosen; Marilyn Mulay; Andy Vanvugt; Melissa Dinolfo; Chisato Tomoda; Masahiro Sugawara; Jerome M Hershman
Journal:  Thyroid       Date:  2007-04       Impact factor: 6.568

9.  Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Authors:  Mathis Grossmann; Erosha Premaratne; Jayesh Desai; Ian D Davis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-03       Impact factor: 3.478

10.  Natalizumab for the treatment of relapsing multiple sclerosis.

Authors:  Richard A Rudick; Michael A Panzara
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.